- Home
- ARI vs DNTH Comparison
ARI vs DNTH Comparison
Compare ARI & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARI
- DNTH
- Stock Information
- Founded
- ARI 2009
- DNTH 2015
- Country
- ARI United States
- DNTH United States
- Employees
- ARI N/A
- DNTH N/A
- Industry
- ARI Real Estate Investment Trusts
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- ARI Real Estate
- DNTH Health Care
- Exchange
- ARI Nasdaq
- DNTH Nasdaq
- Market Cap
- ARI 1.5B
- DNTH 1.5B
- IPO Year
- ARI 2009
- DNTH N/A
- Fundamental
- Price
- ARI $10.01
- DNTH $34.50
- Analyst Decision
- ARI Hold
- DNTH Strong Buy
- Analyst Count
- ARI 4
- DNTH 10
- Target Price
- ARI $10.08
- DNTH $66.38
- AVG Volume (30 Days)
- ARI 882.9K
- DNTH 947.1K
- Earning Date
- ARI 10-29-2025
- DNTH 11-06-2025
- Dividend Yield
- ARI 10.00%
- DNTH N/A
- EPS Growth
- ARI N/A
- DNTH N/A
- EPS
- ARI N/A
- DNTH N/A
- Revenue
- ARI $273,783,000.00
- DNTH $4,854,000.00
- Revenue This Year
- ARI $26.08
- DNTH N/A
- Revenue Next Year
- ARI $18.31
- DNTH N/A
- P/E Ratio
- ARI N/A
- DNTH N/A
- Revenue Growth
- ARI 55.89
- DNTH 17.87
- 52 Week Low
- ARI $7.70
- DNTH $13.37
- 52 Week High
- ARI $11.11
- DNTH $40.16
- Technical
- Relative Strength Index (RSI)
- ARI 40.26
- DNTH 50.57
- Support Level
- ARI $9.91
- DNTH $33.96
- Resistance Level
- ARI $10.41
- DNTH $40.16
- Average True Range (ATR)
- ARI 0.19
- DNTH 2.12
- MACD
- ARI -0.06
- DNTH -0.97
- Stochastic Oscillator
- ARI 16.24
- DNTH 4.03
About ARI Apollo Commercial Real Estate Finance Inc
Apollo Commercial Real Estate Finance Inc is a real estate investment trust that primarily originates, invests in, acquires, and manages commercial first-mortgage loans, subordinate financings, commercial mortgage-backed securities, and other real estate-related debt investments. The subordinate loans and first-mortgage loans account for the vast majority of the portfolio on a cost basis. Property types include residential, retail, healthcare, office, mixed-use, hotel, industrial, multifamily, securities, and other, with residential properties and hotels representing the highest property value. More than a third of the properties are located in New York City, with the other properties located across other regions of the United States, as well as other countries.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.